Search:
« In the Forum - When will I see results?
Loud and Clearer: Hip Hearing Aids »

VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, A Novel Therapy To Treat Obesity

VIVUS, Inc.(Nasdaq: VVUS) today announced positive results from a 200-patient,double-blind, placebo-controlled clinical trial of Qnexa(TM), aninvestigational oral treatment for obesity. In the study conducted by DukeUniversity Medical Center, more than 50% of obese patients in the Qnexatreatment group experienced 10% or more total body weight loss during the24-week study period. Mean weight loss on an intent-to-treat (ITT) basis inthe Qnexa group was 25.1 lbs., compared to 4. [click link for full article]

More: continued here

This entry was posted on Thursday, May 18th, 2006 at 4:05 pm and is filed under Obesity. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply
Sign Up for a free account or learn more.
Submit Articles
Member Login
Top Authors
Most Popular Articles
Submission Guidelines
Ezine Notifications
Article RSS Feeds
About Us
Link to Us
Contact Us
Privacy Policy
Terms of Service
Sponsored Links
center>
Resources
Diet Sites
Food Information
Diet Pills
Fitness Resources
Health Help
Women's Links
Men's Links

Powered by Article Dashboard

Related News


  • OREXIGEN(TM) Therapeutics To Present First Clinical Results For Contrave(TM) To Treat Obesity
    OREXIGEN(TM) Therapeutics, Inc., aprivately held clinical-stage neuroscience company developing a novelstrategic approach to the treatment of obesity, today announced that thecompany's lead program, Contrave(TM), has shown positive results in PhaseII clinical studies and is now being assessed in Phase III trials. Contraveand a companion clinical program Excalia(TM) are rationally formulated,proprietary combinations of marketed CNS products. [click link for full article]


  • Shionogi Announces Positive Results From A Phase IIa Study Of S-2367, A Novel Neuropeptide Y5 Receptor Antagonist For The Treatment Of Obesity
    Shionogi & Co, Ltd. today announced positive top-line efficacy results froma Phase IIa proof-of-concept trial with S-2367, an internally discovereddrug candidate for obesity and related conditions. The unique mechanism ofaction of S-2367 involves blocking receptor binding of neuropeptide Y(NPY), a neurotransmitter involved in regulation of energy balance and foodconsumption. [click link for full article]


  • Positive Results From A Phase IIa Study Of S-2367, A Novel Neuropeptide Y5 Receptor Antagonist For The Treatment Of Obesity
    Shionogi & Co, Ltd. today announced positive top-line efficacy results from a Phase IIa proof-of-concept trial with S-2367, an internally discovered drug candidate for obesity and related conditions. The unique mechanism of action of S-2367 involves blocking receptor binding of neuropeptide Y (NPY), a neurotransmitter involved in regulation of energy balance and food consumption. [click link for full article]


  • VIVUS Announces Issuance Of Key Patent For Qnexa(TM) - A Novel Therapy To Treat Obesity
    VIVUS, Inc.(Nasdaq: VVUS), a pharmaceutical company dedicated to the development andcommercialization of novel therapeutic products addressing obesity andsexual health, today announced that the U.S. Patent and Trademark Officehas issued the company's first patent for Qnexa(TM), an investigational,oral treatment for obesity. This patent, number US 7,056,890 B2, broadlycovers the Qnexa product and its use in the treatment of obesity. The termof this patent extends into 2019. [click link for full article]


  • Manhattan Pharmaceuticals Doses First Patient Group In Phase IIa Trial For OE, Its Oral Obesity Drug Candidate
    Manhattan Pharmaceuticals,Inc. (Amex: MHA) today announced that it commenced dosing the first groupof patients in its Phase IIa clinical trial of oral Oleoyl-estrone (OE),the company's novel drug candidate for the treatment of obesity. Patientrecruitment is ongoing. [click link for full article]